Inventiva added senior leadership to its C-suite as it prepares for a Phase III readout for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) expected in 4Q26. The company appointed a new CFO, chief legal officer, and chief people officer as it looks ahead to the late-stage milestone. Axel-Sven Malkomes, formerly CFO of CureVac and an investment banker, will succeed Jean Volatier as CFO, with Volatier moving to EVP finance and corporate social responsibility. Susan Coles returns to the role of chief legal officer after previously serving as head of legal at Vivet. Pamela Herbster was named chief people officer, bringing prior HR and business operations leadership from Sage Therapeutics.